Literature DB >> 11472206

Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.

M Van der Mey1, A Hatzelmann, G P Van Klink, I J Van der Laan, G J Sterk, U Thibaut, W R Ulrich, H Timmerman.   

Abstract

A series of 4-aryl-substituted cis-4a,5,8,8a-tetra- and cis-4a,5,6,7,8,8a-hexahydro-2H-phthalazin-1-ones with high inhibitory activity toward cAMP-specific phosphodiesterase (PDE4) was synthesized. To study structure-activity relationships various substituents were introduced to the 2-, 3-, and 4-positions of the 4-phenyl ring. Substitution at the 4-position of the phenyl ring was restricted to a methoxy group, probably due to unfavorable steric interactions of larger groups with the binding site. The introduction of many alkoxy substituents including distinct ring systems and functional groups was allowed to the 3-position. It was found that in general the cis-4a,5,8,8a-tetrahydro-2H-phthalazin-1-ones are more potent than their hexahydrophthalic counterparts, the best activity residing in (4-imidazol-1-yl-phenoxy)butoxy analogue 16o (pIC(50) = 9.7).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472206     DOI: 10.1021/jm010838c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

Authors:  John R Cashman; Troy Voelker; Han-Ting Zhang; James M O'Donnell
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

2.  Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

Authors:  Jennifer L Woodring; Nicholas D Bland; Stefan O Ochiana; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2013-08-21       Impact factor: 2.823

3.  Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.

Authors:  Harry P de Koning; Matthew K Gould; Geert Jan Sterk; Hermann Tenor; Stefan Kunz; Edith Luginbuehl; Thomas Seebeck
Journal:  J Infect Dis       Date:  2012-01-30       Impact factor: 5.226

4.  Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

Authors:  Matthew Hoffmann; Gondi Kumar; Peter Schafer; Dorota Cedzik; Lori Capone; Kei-Lai Fong; Zheming Gu; Dennis Heller; Hao Feng; Sekhar Surapaneni; Oscar Laskin; Anfan Wu
Journal:  Xenobiotica       Date:  2011-08-23       Impact factor: 1.908

5.  Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.

Authors:  Sandra Duffy; Melissa L Sykes; Amy J Jones; Todd B Shelper; Moana Simpson; Rebecca Lang; Sally-Ann Poulsen; Brad E Sleebs; Vicky M Avery
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity.

Authors:  Antoni R Blaazer; Abhimanyu K Singh; Erik de Heuvel; Ewald Edink; Kristina M Orrling; Johan J N Veerman; Toine van den Bergh; Chimed Jansen; Erin Balasubramaniam; Wouter J Mooij; Hans Custers; Maarten Sijm; Daniel N A Tagoe; Titilola D Kalejaiye; Jane C Munday; Hermann Tenor; An Matheeussen; Maikel Wijtmans; Marco Siderius; Chris de Graaf; Louis Maes; Harry P de Koning; David S Bailey; Geert Jan Sterk; Iwan J P de Esch; David G Brown; Rob Leurs
Journal:  J Med Chem       Date:  2018-05-01       Impact factor: 7.446

7.  Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening.

Authors:  Erik de Heuvel; Albert J Kooistra; Ewald Edink; Sjors van Klaveren; Jeffrey Stuijt; Tiffany van der Meer; Payman Sadek; Dorien Mabille; Guy Caljon; Louis Maes; Marco Siderius; Iwan J P de Esch; Geert Jan Sterk; Rob Leurs
Journal:  Front Chem       Date:  2021-01-21       Impact factor: 5.221

Review 8.  The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!

Authors:  Daniel N A Tagoe; Titilola D Kalejaiye; Harry P de Koning
Journal:  Front Pharmacol       Date:  2015-09-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.